Cargando…

PB2096: A PHASE 1B/2 STUDY OF GB5121, A NOVEL, HIGHLY SELECTIVE, POTENT, AND CNS-PENETRANT BTK INHIBITOR FOR RELAPSED/REFRACTORY PRIMARY/SECONDARY CNS LYMPHOMA AND PRIMARY VITREORETINAL LYMPHOMA

Detalles Bibliográficos
Autores principales:	Soussain, C., Grommes, C., Ward, R., Peterson, C., Cravets, M., Mathias, A., Sosa, J., Kirby, B., Ding, Z., Yusuf, I., Rose, M., Steinberg, M., Tun, H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Publication Only
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9428960/ http://dx.doi.org/10.1097/01.HS9.0000851216.47783.78

Ejemplares similares

CLRM-15 TRIAL IN PROGRESS: A PHASE 1B/2 STUDY OF GB5121, A NOVEL, HIGHLY SELECTIVE, POTENT, AND CNS-PENETRANT INHIBITOR OF BRUTON’S TYROSINE KINASE (BTKI) FOR RELAPSED/REFRACTORY PRIMARY/SECONDARY CNS LYMPHOMA (R/R PCNSL/SCNSL) AND PRIMARY VITREORETINAL LYMPHOMA (PVRL)
por: Soussain, Carole, et al.
Publicado: (2022)

P1247: GB5121 IS A NOVEL, IRREVERSIBLE, COVALENT BTK INHIBITOR WITH HIGH SELECTIVITY AND CNS-PENETRANCE FOR TREATMENT OF CNS MALIGNANCIES
por: Yusuf, I., et al.
Publicado: (2022)

Update on Novel Therapeutics for Primary CNS Lymphoma
por: Schaff, Lauren R., et al.
Publicado: (2021)

SL3 PRIMARY CNS LYMPHOMA: CURRENT CONCEPTS AND THERAPEUTIC PERSPECTIVES
por: Grommes, Christian
Publicado: (2019)

Primary CNS Lymphoma
por: Phillips, Elizabeth H., et al.
Publicado: (2014)

PB2136: PLANNED-USE GLUCARPIDASE FOR OUTPATIENT HIGH DOSE METHOTREXATE (HD-MTX) ADMINISTRATION IN PATIENTS WITH CNS LYMPHOMA (CNSL) DURING THE COVID-19 PANDEMIC
por: Schaff, L., et al.
Publicado: (2022)

Vitreoretinal lymphoma, secondary to non-CNS systemic lymphoma, masquerading as an infectious retinitis
por: Reddy, Varun, et al.
Publicado: (2019)

PB2334: CENTRAL NERVOUS SYSTEM (CNS) RELAPSE IN DIFFUSE LARGE B-CELL LYMPHOMA: CNS-SAMATYA RISK MODEL
por: Yokus, Osman, et al.
Publicado: (2023)

An audit on the diagnosis of primary CNS lymphoma
por: Joe, Dorothy, et al.
Publicado: (2021)

Primary CNS Lymphoma Masquerading as Ventriculitis
por: Rohatgi, Shalesh, et al.
Publicado: (2022)

Primary vitreoretinal lymphoma
por: Kalogeropoulos, Dimitrios, et al.
Publicado: (2019)

Primary CNS Lymphomas: Challenges in Diagnosis and Monitoring
por: Chiavazza, C., et al.
Publicado: (2018)

Repolarization of tumor infiltrating macrophages and increased survival in mouse primary CNS lymphomas after XPO1 and BTK inhibition
por: Jiménez, Isabel, et al.
Publicado: (2020)

Primary vitreoretinal lymphoma
por: Mulay, Kaustubh, et al.
Publicado: (2015)

Current and Emerging Pharmacotherapies for Primary CNS Lymphoma
por: Prodduturi, Prathima, et al.
Publicado: (2012)

Relapse pattern and prognosis of primary CNS lymphoma
por: Dahiya, Saurabh, et al.
Publicado: (2012)

Expression of Tim‐1 in primary CNS lymphoma
por: Kishimoto, Wataru, et al.
Publicado: (2016)

Sex-Specific Differences in Primary CNS Lymphoma
por: Roetzer, Thomas, et al.
Publicado: (2020)

PB2308: NIVOLUMAB-BASED THERAPY OF RELAPSED OR REFRACTORY PRIMARY LARGE B-CELL LYMPHOMA OF IMMUNE-PRIVILEGED SITES AND DLBCL WITH SECONDARY CNS INVOLVEMENT
por: Gavrilenko, Andrey, et al.
Publicado: (2023)

PB2096: SELINEXOR COMBINED REGIMEN FOR MULTIPLE MYELOMA WITH EXTRAMEDULLARY DISEASE(EMD)
por: Zhong, Yuping, et al.
Publicado: (2023)

Intratumor heterogeneity and T cell exhaustion in primary CNS lymphoma
por: Heming, Michael, et al.
Publicado: (2022)

PB2356: OUTCOMES OF PATIENTS WITH PRIMARY CNS LYMPHOMA (PCNSL) WHO UNDERWENT TREATMENT WITH DEANGELIS, MATRIX, AND PRIMAIN PROTOCOL.: A RETROSPECTIVE SINGLE-CENTER STUDY
por: Richardson, Michelle, et al.
Publicado: (2023)

PB2363: R-MPV FOLLOWED BY CONSOLIDATION REDUCED-DOSE WHOLE-BRAIN RADIOTHERAPY AND CYTARABINE IN NEWLY DIAGNOSED PRIMARY CNS LYMPHOMA: REAL WORLD DATA
por: Amani, Maha EL, et al.
Publicado: (2023)

P1298: THE IRAK-4 INHIBITOR EMAVUSERTIB (CA-4948) FOR THE TREATMENT OF PRIMARY CNS LYMPHOMA
por: Von Roemeling, C., et al.
Publicado: (2022)

Is There an Indication for First Line Radiotherapy in Primary CNS Lymphoma?
por: Seidel, Clemens, et al.
Publicado: (2021)

Multiparametric MR Imaging Features of Primary CNS Lymphomas
por: Talybov, Rustam, et al.
Publicado: (2022)

IL-4 CHALLENGES FOR MANAGEMENT OF PRIMARY CNS LYMPHOMA
por: Nagane, Motoo
Publicado: (2022)

MRI Findings of Primary CNS Lymphoma in 26 Immunocompetent Patients
por: Zhang, Dong, et al.
Publicado: (2010)

ML-10 Tirabrutinib, a second-generation BTK inhibitor in relapsed and refractory primary CNS lymphoma: A single institute study
por: Mishima, Kazuhiko, et al.
Publicado: (2021)

PB2130: RATIONAL FOR METHOTREXATE USAGE FOR THE TREATMENT AND PREVENTION OF CNS INVOLVEMENT IN PATIENTS WITH HIGH-GRADE B-CELL LYMPHOMAS.
por: Misyurina, A., et al.
Publicado: (2022)

Consensus recommendations for MRI and PET imaging of primary central nervous system lymphoma: guideline statement from the International Primary CNS Lymphoma Collaborative Group (IPCG)
por: Barajas, Ramon F, et al.
Publicado: (2021)

Reduced-dose WBRT as consolidation treatment for patients with primary CNS lymphoma: an LOC network study
por: Lesueur, Paul, et al.
Publicado: (2022)

Relapse pattern and prognostic factors for patients with primary CNS lymphoma
por: Suh, Cheolwon, et al.
Publicado: (2012)

Primary CNS lymphoma commonly expresses immune response biomarkers
por: Ou, Alexander, et al.
Publicado: (2020)

An Update on Neurosurgical Management of Primary CNS Lymphoma in Immunocompetent Patients
por: Scheichel, Florian, et al.
Publicado: (2022)

Targeted Therapies and Immune Checkpoint Inhibitors in Primary CNS Lymphoma
por: Wirsching, Hans-Georg, et al.
Publicado: (2021)

Sentinel inflammatory demyelinating lesions preceding primary CNS lymphoma
por: TORRES, Danielle Mesquita, et al.
Publicado: (2021)

Molecular Biomarkers for the Diagnosis of Primary Vitreoretinal Lymphoma
por: Wang, Yujuan, et al.
Publicado: (2011)

Age, gender, and racial differences in incidence and survival in primary CNS lymphoma
por: Villano, J L, et al.
Publicado: (2011)

CD19-directed CAR T-cell therapy for treatment of primary CNS lymphoma
por: Siddiqi, Tanya, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_kn9kb5jrj1nksgu23a2a385lho